Core Insights - Neuronetics, Inc. has announced that TriWest has updated its medical policy to include TMS coverage for adolescents aged 15 and older, marking a significant advancement in treatment accessibility for this demographic [1][2][3] Company Overview - Neuronetics, Inc. specializes in medical technology aimed at improving the quality of life for patients with neurohealth disorders, particularly through its NeuroStar Advanced Therapy [1][5] - The company operates Greenbrook TMS Inc., which provides NeuroStar Advanced Therapy for treating major depressive disorder (MDD) and other mental health conditions across the United States [5] Industry Context - TRICARE coverage is primarily utilized by active and retired military personnel and their families, with the new policy affecting beneficiaries in 26 states [2] - An estimated 4.3 million U.S. adolescents aged 15-21 are affected by major depression, highlighting the need for effective treatment options [3] - NeuroStar TMS therapy is recognized as a safe and effective first-line treatment for adolescents with major depressive disorder, especially given the limited medication options available [3][6] Treatment Efficacy - NeuroStar Advanced Therapy has delivered over 7.9 million treatments and is supported by the largest clinical data set for TMS treatment of depression [5] - The therapy is FDA-cleared for various indications, including as a first-line adjunct treatment for adolescents aged 15-21 with MDD [6]

Core Viewpoint - Neuronetics, Inc. has entered into a three-year exclusive agreement with Elite DNA Behavioral Health to provide transcranial magnetic stimulation (TMS) devices and patient support services across Elite DNA's 30+ locations, aiming to enhance patient access to advanced mental health treatments [1][2][3] Company Overview - Neuronetics, Inc. focuses on developing products that improve the quality of life for patients with neurohealth disorders and is a leader in neuroscience, particularly in TMS therapy [5][6] - Elite DNA Behavioral Health, founded in 2013, is one of Florida's largest mental health networks, providing accessible mental health care through over 30 locations [4] Partnership Details - The collaboration will utilize Neuronetics' Greenbrook platform to enhance operational and patient-support services for Elite DNA, allowing their team to concentrate on patient experience [2][3] - The partnership aims to operationalize strategic values from Neuronetics' Greenbrook acquisition and serves as a model for future collaborations with other organizations [2] Treatment and Services - NeuroStar Advanced Therapy, a non-invasive TMS treatment, has delivered over 7.6 million treatments and is backed by extensive clinical data, making it the leading TMS treatment for major depressive disorder (MDD) in adults [5][6] - Greenbrook treatment centers also provide SPRAVATO (esketamine) Nasal Spray for treatment-resistant depression, having administered over 1.8 million treatments to more than 55,000 patients [6]

Core Insights - Neuronetics, Inc. plans to release its third quarter 2025 financial and operating results on November 4, 2025, before market open, followed by a conference call at 8:30 a.m. Eastern Time [1] Company Overview - Neuronetics, Inc. focuses on improving the quality of life for patients with neurohealth disorders through innovative medical technology, particularly the NeuroStar® Advanced Therapy, which is a leading provider of Transcranial Magnetic Stimulation (TMS) [3] - The company operates Greenbrook TMS Inc. treatment centers across the U.S., offering NeuroStar Advanced Therapy for Major Depressive Disorder (MDD) and other mental health conditions [3] - NeuroStar Advanced Therapy has delivered over 7.6 million treatments and is supported by the largest clinical data set for TMS treatments for depression, including the world's largest depression outcomes registry [3] Treatment Offerings - NeuroStar Advanced Therapy is FDA-cleared for adults with MDD and is also indicated for adolescents aged 15-21 as an adjunct treatment [4] - Greenbrook treatment centers provide SPRAVATO® (esketamine) Nasal Spray for treatment-resistant depression (TRD) and for adults with MDD exhibiting acute suicidal ideation [3][4] - Greenbrook has administered over 1.8 million treatments to more than 55,000 patients suffering from depression [3]

Core Points - New York State Medicaid will cover Transcranial Magnetic Stimulation (TMS) services for adults diagnosed with major depressive disorder (MDD) starting October 1, 2025, for fee-for-service members and November 1, 2025, for those in Managed Care Plans [1][2] - This policy change will benefit nearly 1 million individuals with fee-for-service Medicaid and over 4.4 million individuals with Managed Care Organizations in New York [2] - Major depressive disorder affects 21 million adults in the U.S., with 6.4 million unable to tolerate or receiving inadequate relief from antidepressants [3] Company Overview - Neuronetics, Inc. is a medical technology company focused on neurohealth disorders and is the maker of NeuroStar Advanced Therapy, the leading provider of TMS [1][5] - NeuroStar Advanced Therapy is a non-drug, non-invasive treatment that has shown an 83% response rate and a 62% remission rate for MDD patients [3] - Neuronetics operates Greenbrook TMS Inc. treatment centers across the U.S., providing NeuroStar Advanced Therapy and has delivered over 7.6 million treatments [5] Industry Context - The decision by New York State Medicaid reflects a growing recognition of TMS as an evidence-based treatment for depression [2] - Neuronetics is the only TMS company with a dedicated health policy team advocating for health policy updates [4] - The NeuroStar Advanced Therapy System is FDA-cleared for various indications, including MDD and anxiety symptoms in adults [6]

Core Insights - Neuronetics, Inc. has published significant findings demonstrating the effectiveness of NeuroStar TMS in treating adolescents and young adults with depression, as reported in a leading medical journal [1][2] Company Overview - Neuronetics is a medical technology company focused on improving the quality of life for patients with neurohealth disorders through innovative products [4] - The company operates Greenbrook TMS Inc., which provides NeuroStar Advanced Therapy for major depressive disorder (MDD) and other mental health conditions across the United States [4] Treatment Efficacy - The study based on the NeuroStar TrakStar Clinical Database involved 1,283 patients, with approximately 70% reporting clinically meaningful improvement in depression symptoms, while less than 1% experienced worsening [2][3] - The results for adolescents and young adults align with previous findings in adult populations, indicating a strong correlation between the number of treatment sessions completed and clinical improvement [2] Market Opportunity - With one in five adolescents experiencing major depressive disorder and limited FDA-approved medications available, NeuroStar TMS presents a significant opportunity to provide a safe and effective treatment option for this demographic [3] - Since receiving FDA clearance as an add-on therapy for adolescents aged 15-21 in March 2024, there has been over a one-third increase in the number of adolescents treated with NeuroStar [2]

Core Insights - NeuroStar, a Silver Sponsor at the 13th Annual Clinical TMS Society (CTMSS) Meeting, is committed to clinical innovation and excellence in mental health care [1][2] - The company will present two significant poster presentations based on the TrakStar data set, which is the largest real-world outcomes database in TMS [2][3] - NeuroStar aims to optimize TMS efficacy and expand its use into new populations and protocols, reinforcing its leadership in the psychiatric community [3] Company Updates - NeuroStar will present a retrospective analysis comparing clinical outcomes between its proprietary Figure-8 coil and Brainsway's H-coil in treating depression [2] - The company is evaluating personalized qEEG-informed protocols for TMS therapy, demonstrating operational feasibility with the NeuroStar TMS System [4] - NeuroStar has delivered over 7.4 million treatments and operates Greenbrook TMS centers across the U.S. for treating Major Depressive Disorder (MDD) and other mental health disorders [6] Event Participation - The CTMSS Meeting will take place from June 11-14 in San Diego, CA, where NeuroStar will also participate in the PULSES Course for TMS providers [2] - Presentations will include data on elderly adults (age 70 and older) with MDD treated with TMS, and a retrospective analysis from 200 Greenbrook centers [7]